Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Pembrolizumab in Patients With Advanced Gynaecological Clear Cell Cancer

NCT03425565 is registered in ClinicalTrials.gov with University College, London as lead sponsor.

NCT NCT03425565
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03425565 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Pembrolizumab in Patients With Advanced Gynaecological Clear Cell Cancer
Lead sponsor
University College, London
Phase
Phase 2
Overall status
Completed
Start date
February 18, 2019
Completion date
September 18, 2026
Enrollment
48 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, clear cell tumor, gynecologic cancer